이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

InnoCan Pharma 관리

관리 기준 확인 3/4

InnoCan Pharma's CEO는 Iris Bincovich, Jan2018 에 임명되었습니다 의 임기는 6.42 년입니다. 총 연간 보상은 $ 337.00K, 79.5% 로 구성됩니다. 79.5% 급여 및 20.5% 보너스(회사 주식 및 옵션 포함). 는 CA$ 1.23M 가치에 해당하는 회사 주식의 1.76% 직접 소유합니다. 1.23M. 경영진과 이사회의 평균 재임 기간은 각각 4.9 년과 4.6 년입니다.

주요 정보

Iris Bincovich

최고 경영자

US$337.0k

총 보상

CEO 급여 비율	79.5%
CEO 임기	6.5yrs
CEO 소유권	1.8%
경영진 평균 재임 기간	5yrs
이사회 평균 재임 기간	4.7yrs

최근 관리 업데이트

It's Probably Less Likely That InnoCan Pharma Corporation's (CSE:INNO) CEO Will See A Huge Pay Rise This Year

May 04

Recent updates

It's Probably Less Likely That InnoCan Pharma Corporation's (CSE:INNO) CEO Will See A Huge Pay Rise This Year

May 04

CEO 보상 분석

Iris Bincovich 의 보수는 InnoCan Pharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$5m
Dec 31 2023	US$337k	US$268k	-US$5m
Sep 30 2023	n/a	n/a	-US$5m
Jun 30 2023	n/a	n/a	-US$3m
Mar 31 2023	n/a	n/a	-US$4m
Dec 31 2022	US$401k	US$291k	-US$4m
Sep 30 2022	n/a	n/a	-US$3m
Jun 30 2022	n/a	n/a	-US$7m
Mar 31 2022	n/a	n/a	-US$6m
Dec 31 2021	US$645k	US$300k	-US$10m
Sep 30 2021	n/a	n/a	-US$16m
Jun 30 2021	n/a	n/a	-US$14m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$361k	US$223k	-US$10m
Sep 30 2020	n/a	n/a	-US$3m
Jun 30 2020	n/a	n/a	-US$5m
Mar 31 2020	n/a	n/a	-US$3m
Dec 31 2019	US$384k	US$219k	-US$3m
Sep 30 2019	n/a	n/a	-US$6m
Dec 31 2018	US$165k	US$54k	-US$2m

보상 대 시장: Iris 의 총 보상 ($USD 337.00K )은 Canadian 시장( $USD 175.07K ).

보상과 수익: Iris 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Iris Bincovich (54 yo)

6.5yrs

테뉴어

US$337,000

보상

Mrs. Iris Bincovich has been Member of Advisory Board at Ayurcann Holdings Corp. since May 2021. Mrs. Bincovich has been the Chief Executive Officer at InnoCan Pharma Corporation since January 2018 and has...

리더십 팀

이름	위치	테뉴어	보상	소유권
Ron Mayron	Executive Chairman	4.8yrs	US$136.00k	1.84% $ 1.3m
Iris Bincovich	CEO & Director	6.5yrs	US$337.00k	1.76% $ 1.2m
Nelson Halpern	Chief Financial Officer	5.4yrs	US$64.00k	0.13% $ 88.3k
Roni Kamhi	COO & CEO of BI Sky Global and Director	1.9yrs	US$230.00k	0.079% $ 54.4k
Eyal Flom	Director & Company Secretary	4.5yrs	데이터 없음	0.85% $ 581.9k
Yoram Drucker	Founder & Executive VP of Business Development	no data	US$173.00k	데이터 없음

5.0yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: INNO 의 관리팀은 경험 ( 4.9 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Ron Mayron	Executive Chairman	4.8yrs	US$136.00k	1.84% $ 1.3m
Iris Bincovich	CEO & Director	4.8yrs	US$337.00k	1.76% $ 1.2m
Roni Kamhi	COO & CEO of BI Sky Global and Director	less than a year	US$230.00k	0.079% $ 54.4k
Eyal Flom	Director & Company Secretary	4.8yrs	데이터 없음	0.85% $ 581.9k
Peter Bloch	Independent Director	4.5yrs	데이터 없음	0.026% $ 17.7k
Joseph Pergolizzi	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Yechezkel Barenholz	Scientific Advisor	no data	데이터 없음	데이터 없음
Joshua Lintern	Independent Director	4.8yrs	데이터 없음	0.057% $ 39.3k
Ralph C. Bossino	Director	4.8yrs	데이터 없음	0.088% $ 60.4k
Josef Geldwert	Scientific Advisor	no data	데이터 없음	데이터 없음
Mitchell Kline	Member of Scientific Advisory Committee	3.3yrs	데이터 없음	데이터 없음
Izhar Shay	Member of Advisory Committee	3yrs	데이터 없음	데이터 없음

4.7yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 이사회: INNO 의 이사회는 경험(평균 재직 기간 4.6 년)으로 간주됩니다.

InnoCan Pharma 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

It's Probably Less Likely That InnoCan Pharma Corporation's (CSE:INNO) CEO Will See A Huge Pay Rise This Year

InnoCan Pharma Corporation, Annual General Meeting, May 09, 2024

InnoCan Pharma Corporation Announces Appointment of Dr. Joseph V. Pergolizzi to its Scientific Advisory Board

Innocan Pharma Corporation Announces the Addition of Givi Topchishvili, to Advisory Committee, as A Business Strategy Adviser

Less than half of directors are independent

Less than half of directors are independent

Recent updates

First quarter 2024 earnings released: US$0.007 loss per share (vs US$0.005 loss in 1Q 2023)

Innocan Pharma Corporation Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey

It's Probably Less Likely That InnoCan Pharma Corporation's (CSE:INNO) CEO Will See A Huge Pay Rise This Year

Full year 2023 earnings released: US$0.018 loss per share (vs US$0.015 loss in FY 2022)

InnoCan Pharma Corporation announced that it has received CAD 1.98821 million in funding

InnoCan Pharma Corporation, Annual General Meeting, May 09, 2024

InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding

Third quarter 2023 earnings released: US$0.008 loss per share (vs US$0.001 loss in 3Q 2022)

InnoCan Pharma Corporation announced that it has received CAD 1.627682 million in funding

InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding

InnoCan Pharma Corporation Announces Appointment of Dr. Joseph V. Pergolizzi to its Scientific Advisory Board

Second quarter 2023 earnings released: US$0.002 loss per share (vs US$0.007 loss in 2Q 2022)

InnoCan Pharma Corporation announced that it has received CAD 1.934239 million in funding

New minor risk - Shareholder dilution

InnoCan Pharma Corporation announced that it expects to receive CAD 1.934239 million in funding

New minor risk - Shareholder dilution

InnoCan Pharma Corporation announced that it has received CAD 3.9606 million in funding

Innocan Pharma Corporation Submits New Patent Applications for Advanced Pain Relief Technology

First quarter 2023 earnings released: US$0.005 loss per share (vs US$0.003 loss in 1Q 2022)

InnoCan Pharma Corporation Announces Successful Treatment of Billy with Liposomal-CBD Injection in Pre-Clinical Trial

Full year 2022 earnings released: US$0.015 loss per share (vs US$0.045 loss in FY 2021)

InnoCan Pharma Corporation announced that it has received CAD 0.4955 million in funding

Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?

Third quarter 2022 earnings released: US$0.001 loss per share (vs US$0.016 loss in 3Q 2021)

Innocan Pharma Corporation Announces the Addition of Givi Topchishvili, to Advisory Committee, as A Business Strategy Adviser

Less than half of directors are independent

Innocan Pharma Corporation Announces Additional Positive Results in New Preclinical Trial Involving A Dog with Refractory Epilepsy

Second quarter 2022 earnings released

InnoCan Pharma Corporation Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology

We Think InnoCan Pharma (CSE:INNO) Can Afford To Drive Business Growth

InnoCan Pharma Corporation Announces Results Approaches 100% Bioavailability Following Subcutaneous Injection of Its CBD Proprietary LPT Delivery System in A Clinical Study Conducted on Dogs Suffering from Pain

InnoCan Pharma Corporation Files PCT Patent Application for Novel Composition for Preventing and Treating Hair Loss

Innocan Pharma Corporation Files PCT Patent Application for Diabetic Symptoms

InnoCan Pharma Corporation Reports Positive Results from Recent Preclinical Trial on Epileptic Seizures on Dog Using LPT

Innocan Pharma Corporation Reports Successful Preclinical Dog-Trial Results Regarding Pain Management

Innocan Pharma Corporation Announces Filing of PCT Patent Application for Vaginal Atrophy Treatment

First quarter 2022 earnings released

Less than half of directors are independent

Companies Like InnoCan Pharma (CSE:INNO) Are In A Position To Invest In Growth

InnoCan Pharma Corporation Reports Successful FDA Required Characterization of Highly CBD Loaded Liposome Platform

Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?

Innocan Pharma Corporation Cbd Integrated Anti-Aging Sleeping Mask Demonstrates A Reduction of the Appearance of Wrinkles by Up to 28.8% in 4 Weeks of Clinical Study

Innocan Pharma Corporation Completes a Cosmetic Clinical Study of SHIR® CBD Eye Serum on 22 Volunteers

Innocan Pharma Announces Patent Application for Novel Cannabis-Based Vaginal Moisturizer and Lubricant Treatment

Innocan Pharma's Liposome Platform Technology Demonstrates a 7-Week Prolonged Release of CBD into Bloodstream in Recent Animal Study

Innocan Pharma's CBD Loaded Liposome Platform Technology Receives Positive Results from Recent Animal Study

We Think InnoCan Pharma (CSE:INNO) Needs To Drive Business Growth Carefully

Innocan Pharma Announces Patent Application for Novel Cannabis-Based Anti-Itch Treatment

InnoCan Pharma Corporation Announces the Completion of Its First Full-Scale Manufacturing Run in the US and the Launching of Its US Commercial Online Platform

Innocan Pharma Announces Successful Production of CBD Loaded Liposomes Under Aseptic Conditions

New 90-day high: CA$0.41

InnoCan Pharma Corporation Announces Successful Completion of a Large-Scale Production of Exosomes

InnoCan Pharma Corporation announced that it has received CAD 2.367804 million in funding

New 90-day high: CA$0.31

InnoCan Pharma Corporation Announces the Completion of Its First Full-Scale Manufacturing Run in Europe and the Commencement of its Full-Scale Manufacturing Run in the USA

Innocan Pharma Corporation Announces the Launch of Two Therapeutic Studies on Small and Large Animals Examining the Therapeutic Efficacy of CBD Loaded Liposome Platform Technology in Relevant Diseases

New 90-day high: CA$0.30

Innocan Pharma's Clinical Study in the US Indicates That More Than 90% of Participants Experienced Pain Reduction After Using Innocan's Relief & Go OTC Pain Relief Spray

Innocan Pharma's Cosmetic Clinical Study Indicates a 90% Wrinkle Reduction After Using Its SHIR(TM) Premium CBD Facial Serum

Innocan Pharma Corporation Provides Clinical Update of its Unique CBD-Loaded Liposome Platform Technology for Injectable CBD

New 90-day high: CA$0.24

InnoCan Pharma Corporation Completes Successful Cosmetic Clinical Studies

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령